Published in J Rheumatol on April 01, 2000
Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One (2012) 1.63
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord (2008) 1.63
Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis (2001) 1.63
Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res (2000) 1.35
Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis. Health Serv Res (2010) 1.27
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis (2004) 1.14
Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol (2005) 1.12
Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis (2005) 1.07
The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis (2005) 1.06
Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis. Clin Ther (2013) 0.98
Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis (2002) 0.95
Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis (2011) 0.94
Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol (2003) 0.85
Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res Ther (2004) 0.81
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics (2008) 0.80
Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics (2009) 0.80
Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy. Clin Rheumatol (2009) 0.78
Anti-tumour necrosis factor alpha therapy: can we afford it? Ann Rheum Dis (2005) 0.77
A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors. Ann Rheum Dis (2006) 0.77
Where is biological therapy going? Arthritis Res (2000) 0.77
Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. RMD Open (2017) 0.75
The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases. Biomark Insights (2007) 0.75
Effect of N-Feruloylserotonin and Methotrexate on Severity of Experimental Arthritis and on Messenger RNA Expression of Key Proinflammatory Markers in Liver. J Immunol Res (2016) 0.75
New Therapies for Rheumatoid Arthritis. Med J Armed Forces India (2011) 0.75
Protective effect of higenamine ameliorates collagen-induced arthritis through heme oxygenase-1 and PI3K/Akt/Nrf-2 signaling pathways. Exp Ther Med (2016) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 10.67
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum (2001) 3.15
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology (1999) 2.80
Fluorescence resonance energy transfer from cyan to yellow fluorescent protein detected by acceptor photobleaching using confocal microscopy and a single laser. J Microsc (2003) 2.74
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 2.62
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum (2000) 2.26
Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum (1998) 1.96
Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (1998) 1.93
Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum (1997) 1.92
Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum (2001) 1.84
Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis (2007) 1.82
Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol (1995) 1.68
Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. Arthritis Rheum (2005) 1.58
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
The role of methotrexate in the management of steroid-dependent asthma. Chest (1994) 1.46
Autoimmunity to collagen in adjuvant arthritis of rats. J Clin Invest (1980) 1.44
Cyclosporine in the treatment of psoriatic arthritis. Arch Dermatol (1989) 1.41
Autoantibodies as predictors of disease. J Clin Invest (2001) 1.37
Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum (1995) 1.20
Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med (1997) 1.18
Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med (1985) 1.13
Gold does not alter the arthritic, humoral, or cellular responses in rats with type II collagen-induced arthritis. Arthritis Rheum (1980) 1.12
Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis (2001) 1.10
Lupus nephritis. Classification, prognosis, immunopathogenesis, and treatment. Rheum Dis Clin North Am (1994) 1.08
Effect of psychological stress on the induction of arthritis in rats. Arthritis Rheum (1980) 1.08
Autoimmunity to collagen: a shared feature of psoriatic and rheumatoid arthritis. Arthritis Rheum (1981) 1.05
MRI in osteoarthritis of the hip: gradations of severity. Magn Reson Imaging (1988) 1.04
Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Ann Rheum Dis (2008) 1.03
CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. Br J Rheumatol (1996) 1.01
Progress in the treatment of rheumatoid arthritis. JAMA (2001) 1.01
Cervical spine involvement in rheumatoid arthritis: MR imaging. Radiology (1987) 1.00
Sonographic evaluation of the cartilage of the knee. Radiology (1984) 1.00
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol (2014) 0.99
Identification of a 2-Md plasmid from Shigella flexneri associated with reactive arthritis. Arthritis Rheum (1989) 0.99
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2013) 0.98
Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol (1999) 0.97
Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States. Ann Rheum Dis (2004) 0.96
Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am (1994) 0.96
Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome. Am J Med (1987) 0.95
In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2013) 0.94
Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum (1995) 0.93
Type II collagen-induced auricular chondritis. Arthritis Rheum (1982) 0.92
Correlation of angiographic abnormalities with disease manifestations and disease severity in polyarteritis nodosa. J Rheumatol (1987) 0.91
Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). Arthritis Rheum (1998) 0.90
Association between reactive arthritis and antecedent infection with Shigella flexneri carrying a 2-Md plasmid and encoding an HLA-B27 mimetic epitope. Arthritis Rheum (1993) 0.89
Inhibition of leukocyte-endothelial adherence following thermal injury. J Surg Res (1992) 0.89
MRI and 2D-CSI MR spectroscopy of the brain in the evaluation of patients with acute onset of neuropsychiatric systemic lupus erythematosus. Neuroradiology (2005) 0.87
Systemic lupus erythematosus. Diagnosis and treatment. Med Clin North Am (1997) 0.87
Nitric oxide--friend or foe in arthritis? J Rheumatol (1998) 0.87
Mononuclear cell retention in rheumatoid synovial tissue engrafted in severe combined immunodeficient (SCID) mice is up-regulated by tumour necrosis factor-alpha (TNF-alpha) and mediated through intercellular adhesion molecule-1 (ICAM-1). Clin Exp Immunol (1996) 0.86
Monoclonal antibody to intercellular adhesion molecule-1 reduces cardiac contractile dysfunction after burn injury in rabbits. J Surg Res (1996) 0.86
CTLA-4 gene polymorphisms and systemic lupus erythematosus in a population-based study of whites and African-Americans in the southeastern United States. Lupus (2004) 0.86
Isolated small-vessel angiitis of the central nervous system. Arch Neurol (1988) 0.86
Connective tissue disease can develop in rats either spontaneously or after total lymphoid irradiation. J Rheumatol (1984) 0.85
MR imaging of systemic lupus erythematosus involving the brain. AJR Am J Roentgenol (1985) 0.85
Inhibition of leukocyte adherence and susceptibility to infection. J Surg Res (1993) 0.85
Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease. Arthritis Rheum (1998) 0.84
Barbiturate inhibition of lymphocyte function. Differing effects of various barbiturates used to induce coma. J Neurosurg (1982) 0.83
Interference with the function of leukocyte adhesion molecules by monoclonal antibodies: a new approach to burn injury. Eur J Pediatr Surg (1994) 0.83
Therapeutic approaches to the treatment of rheumatoid disease. Med Clin North Am (1986) 0.83
Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med (1997) 0.83
Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections. Curr Opin Rheumatol (1999) 0.82
Self-efficacy for exercise, more than disease-related factors, is associated with objectively assessed exercise time and sedentary behaviour in rheumatoid arthritis. Scand J Rheumatol (2014) 0.82
Update on immunosuppressive therapy. Curr Opin Rheumatol (1998) 0.82
Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus. J Rheumatol (2001) 0.82
A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum (1996) 0.81
Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol (2012) 0.81
Inhibition of leukocyte adherence in a rabbit model of major thermal injury. J Burn Care Rehabil (1994) 0.81
A case of sustained massive gabapentin overdose without serious side effects. Ther Drug Monit (1999) 0.81
Defective CD2 pathway T cell activation in systemic lupus erythematosus. Arthritis Rheum (1991) 0.80
Systemic cytomegalovirus infection mimicking an exacerbation of Wegener's granulomatosis. J Rheumatol (1993) 0.80
Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol (1996) 0.80
Giant cell arteritis and peripheral neuropathy: a report of 2 cases and review of the literature. J Rheumatol (1987) 0.79
Abrogation of type II collagen-induced arthritis in rats by psychological stress. Trans Assoc Am Physicians (1979) 0.78
The role of the laboratory in the evaluation of rheumatic diseases. Clin Cornerstone (1999) 0.78
Immunosuppression by fractionated total lymphoid irradiation in collagen arthritis. Arthritis Rheum (1982) 0.78
Immunologic and clinical effects of cytotoxic drugs used in the treatment of rheumatoid arthritis and systemic lupus erythematosus. Concepts Immunopathol (1989) 0.78
Septic arthritis caused by treatment resistant Pseudomonas cepacia. Ann Rheum Dis (1990) 0.78
The use of analgesics in the management of pain in rheumatic diseases. Rheum Dis Clin North Am (1999) 0.77
Effect of inhibiting leukocyte integrin (CD18) and selectin (L-selectin) on susceptibility to infection with Pseudomonas aeruginosa. J Trauma (1994) 0.77
The anti-La response of a single MRL/Mp-lpr/lpr mouse: specificity for DNA and VH gene usage. Eur J Immunol (1994) 0.77
Delayed lupus nephritis. Ann Rheum Dis (2008) 0.77
Systemic lupus during pregnancy with refractory alveolar haemorrhage: recovery following termination of pregnancy. Lupus (1997) 0.76
A case report: the use of ketamine and midazolam intravenous sedation for a child undergoing radiotherapy. AANA J (1993) 0.76
Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis. Clin Exp Rheumatol (2009) 0.76
Radiographic joint damage in rheumatoid arthritis: a community-based perspective. Arthritis Rheum (2001) 0.75
Serum levels of soluble CD44 in primary Sjögren's syndrome. J Rheumatol (2000) 0.75
Injection of corticosteroids into joints. Orthop Rev (1994) 0.75
Bedside science reduces laboratory art. Circulation (1995) 0.75
Differential effects of monoclonal antibody blockade of adhesion molecules on in vivo susceptibility to soft tissue infection. Infect Immun (1995) 0.75